Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-A02983-36 | Registry Identifier | IDRCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this open, multi center trial is to evaluate a new biological replacement for synthetic slings in the treatment of female stress urinary incontinence.
It was estimated that more than 9 million French people are affected by urinary incontinence, of which 1% are treated surgically. Indeed, if medical treatment or rehabilitation fails, surgical treatment must be considered. Sling implantation is a commonly used surgical technique to treat stress urinary incontinence as it allows for a reduction in surgery time and morbidity and can be placed under local anesthesia. However, the risk of complications associated with the use of synthetic products is high and contributes to the recent decline of popularity of synthetic slings. As the demand for incontinence treatment remains high, fascia autograft surgeries are being proposed, even though they require an additional surgical procedure and expose the patient to complications at the donor site of the graft.
The study product aims to address the growing need for a safer but equally effective implant to avoid autografting while keeping the standard surgical technique.
The aim of this exploratory study is to evaluate a biological sling replacement to failed synthetic slings in the treatment of female stress urinary incontinence.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| UVT | Experimental | Biological sling used as a replacement of the synthetic sling. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| UVT | Biological | Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator. |
| Measure | Description | Time Frame |
|---|---|---|
| No major signs of incontinence | Use of less than 2 pads a day | 6 months |
| No complication related to investigational product | Evaluation of urinary retention, dysuria, local inflammation, irritation of suture and suspension areas, and other indirect symptoms | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Decrease of the signs of complications of the first surgery | Monitoring of urinary retention, dysuria, local inflammation, irritation of suture and suspension areas, and other indirect symptoms | 15 days, 6 weeks, 3 months, 6 months, 12 months |
| Decrease of pain and analgesic consumption |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôtel-Dieu, CHU de Nantes | Nantes | 44000 | France | |||
| Hôpital de la Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014550 | Urinary Incontinence, Stress |
| ID | Term |
|---|---|
| D014549 | Urinary Incontinence |
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Pain evaluated from 0: no pain to 10: worst imaginable pain on visual analog scale (VAS) |
| 15 days, 6 weeks, 3 months, 6 months, 12 months |
| Progressive recuperation of continence | Continence evaluated by uroflow test and 3-day voiding diary | 15 days, 6 weeks, 3 months, 6 months, 12 months |
| Decrease of Urinary Incontinence (UI) severity | Decrease in the score of the International Consultation on Incontinence Questionnaire - Urinary Incontinence - Short Form (ICIQ-UI-SF) (0 = no UI, 21 = very severe UI) | 6 weeks, 3 months, 6 months, 12 months |
| Decrease of distress caused by UI symptoms | Decrease of the Urogenital Distress Inventory (UDI-6) score (0 = no distress caused by UI symptoms, 100 = highest possible distress cause by UI symptoms) | 6 weeks, 3 months, 6 months, 12 months |
| Improvement of health-related quality of life | Decrease of the Incontinence Impact Questionnaire (IIQ-7) score (0 = no impact of UI on health-related quality of life, 100 = highest possible impact of UI on health-related quality of life) | 6 weeks, 3 months, 6 months, 12 months |
| Paris |
| 75013 |
| France |
| Hôpital Lyon Sud, Hospices Civils de Lyon | Pierre-Bénite | 69310 | France |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |